Dr. Eszter Nagy is a serial entrepreneur with 20+ years of biotech experience in discovery, translational research, pre-clinical and early clinical product development. Dr. Nagy founded CEBINA in 2018  where she acts as CEO and CSO, and is co-founder of Mag-Lab GmbH (2021), Algonist Biotechnologies GmbH (2020), Calyxha Biotechnologies GmbH (2019), Eveliqure Biotechnologies GmbH (2012), a clinical-stage company where she raised a combined funding of €36M, 85% of it from non-dilutive sources. 

​

In 2010, she co-founded Arsanis, Inc. (ASNS, NASDAQ, now X4 Biopharmaceuticals, XFOR), where she served as CSO and managing director of the wholly-owned subsidiary, Arsanis Biosciences GmbH (Vienna, Austria) for 8 yrs. Under her leadership, Arsanis developed several anti-infective monoclonal antibody product candidates with a lead program in Phase 2, financed by Series A-D financing of ~$40M and ~€16M non-dilutive funding prior to Initial Public Offering in 2017. 

​

Before that, Dr. Nagy was SVP of Research at Intercell AG (now Valneva SAS), where she worked for 12 years and was responsible for discovery and research of 20 infectious disease and vaccine projects.

​

Previously Dr. Nagy worked in academic research in the fields of molecular biology, cellular immunology, and cellular physiology at several institutions in the US (Dartmouth College and Medical School, Hanover, NH, and Roswell Park Cancer Institute, Buffalo, NY) and in Hungary (Medical University, Pécs, Hungary). She completed her medical degree in Hungary (Univ. Med. School of Pécs) and obtained her PhD in molecular biology. Eszter Nagy has published over 85 original publications and book chapters. She is the holder of more than 40 patents in the field of vaccines, anti-infectives and biotechnology.